Description:
The primary objective of the current study is to demonstrate the equivalent efficacy of
rituximab (DRL_RI) and MabThera® in subjects with Low Tumor Burden Follicular Lymphoma
(LTB-FL).
Also evaluated by Pharmacokinetic, safety, and immunogenicity assessment between a proposed
biosimilar (DRL_RI) and the RMP, as an component of clinical study program, and collectively
providing the evidence of biosimilarity.
The study will compare the safety and efficacy of DRL_RI vs MabThera in patients with Low
Tumor Burden Follicular Lymphoma (LTB-FL). The primary objective is to establish comparative
efficacy as measured by ORR at week 28
Title
- Brief Title: Compare the Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma (FLINTER)
- Official Title: A Double-blind, Parallel-group, Phase III Study to Compare the Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in Subjects With Previously Untreated (CD)20-Positive LTB Follicular Lymphoma
Clinical Trial IDs
- ORG STUDY ID:
RI-01-006
- NCT ID:
NCT03976102
Conditions
Interventions
Drug | Synonyms | Arms |
---|
DRL_RI (Proposed rituximab biosimilar) | | Arm A: DRL_RI |
Purpose
The primary objective of the current study is to demonstrate the equivalent efficacy of
rituximab (DRL_RI) and MabThera® in subjects with Low Tumor Burden Follicular Lymphoma
(LTB-FL).
Also evaluated by Pharmacokinetic, safety, and immunogenicity assessment between a proposed
biosimilar (DRL_RI) and the RMP, as an component of clinical study program, and collectively
providing the evidence of biosimilarity.
The study will compare the safety and efficacy of DRL_RI vs MabThera in patients with Low
Tumor Burden Follicular Lymphoma (LTB-FL). The primary objective is to establish comparative
efficacy as measured by ORR at week 28
Detailed Description
It is planned to randomise approx. 284 subjects at approximately 130 study sites worldwide.
Subjects with LTB-FL will be randomized to receive either DRL_RI or MabThera®. Till date, 68
patients have been randomized for the study.
The study specific objectives are mentioned below:
Primary Objective:
- To demonstrate the equivalent efficacy of DRL_RI (biosimilar rituximab) and MabThera in
subjects with CD20-positive, LTB FL, as measured by overall response rate (ORR) at Week
28 Secondary Objectives:
- To compare the progression-free survival (PFS), overall survival (OS), and duration of
response (DOR) of DRL_RI with MabThera in subjects with CD20-positive, LTB FL.
- To compare the safety, tolerability, and immunogenicity of DRL_RI with MabThera in
subjects with CD20-positive, LTB-FL.
Exploratory Objectives
- To explore the pharmacokinetic (PK) parameters of DRL_RI and MabThera, using a
population-PK modelling approach.
- To explore the pharmacodynamic parameters of DRL_RI and MabThera.
Trial Arms
Name | Type | Description | Interventions |
---|
Arm A: DRL_RI | Experimental | DRL_RI (rituximab-Dr. Reddy's Lab) for infusion 375 mg/m2 administered via IV infusion on Days 1, 8, 15, 22 and Weeks 12, 20, 28 and 36 | - DRL_RI (Proposed rituximab biosimilar)
|
Arm B: MabThera® | Active Comparator | MabThera® for infusion 375 mg/m2 administered via IV infusion on Days 1, 8, 15, 22 and Week 12, 20, 28 and 36. | |
Eligibility Criteria
Inclusion Criteria:
1. Subject is Male or female subjects aged ≥18 years of age.
2. Subject is histologically confirmed, Grade 1-3a, previous ly untreated, CD20-pos
itive.
3. Subject has Ann Arbor Stage II to IV and ECOG status of 0 to 1.
4. Subject has Low tumor burden follicular lymphoma as per Groupe d'Etude des Lymphomes
Folliculaires (GELF) Criteria
5. Subject has at least 1 measurable tumor mass in 2 dimensions, and the mass must be:
1. Nodal lesion >15 mm in the longest dimension; or
2. Noda l lesion >10 mm to he longest dimension; dimens ion and >10 mm in the
shortest dimension; or
3. Extra-nodal lesion with both long and short dimensions ≥10 mm.
6. Subject has Life expectancy ≥3 months.
7. If female subject, then subject should be non-pregnant, non-lactating.
Exclusion Criteria:
1. Subject with prior use of rituximab or any CD20 monoclonal antibody for any reason.
2. Subjects with known hypersensitivity to rituximab or its excipients, or to proteins of
murine or other foreign origin.
3. Any prior therapy for follicular lymphoma (including but not limited to chemotherapy,
radiotherapy) or subjects on chronic supra-substitutive doses of systemic
gluco-corticosteriods.
4. Subjects who, in the opinion of the Investigator, require additional concomitant
treatment for lymphoma.
5. Evidence of histologic transformation to high grade lymphoma or diffuse large B-cell
lymphoma.
6. Subjects with known sero-positivity for or history of active viral infection with
human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) positive or
hepatitis B core antibody positive, hepatitis C virus (HCV) antibody positive.
7. Subjects who have received a live vaccine within last 3 months of the first
administration of study drug.
8. Subjects with history or presence of a medical condition or disease that in the
Investigator's opinion would place the subject at an unacceptable risk for study
participation.
9. Participation in any clinical study or having taken any investigational therapy
(within 2-months of the first dose of study drug.
10. Women of childbearing potential who do not consent to use highly effective methods of
birth control.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Overall Response Rate (ORR) measured for follicular lymphoma |
Time Frame: | Month 7 (Week 28) |
Safety Issue: | |
Description: | The primary endpoint is ORR, defined as the proportion of subjects in each treatment group that achieve complete response (CR), unconfirmed complete response (CRu) or partial response (PR) at Month 7 (Week 28) with the response criteria for malignant lymphoma |
Secondary Outcome Measures
Measure: | Progression-free survival |
Time Frame: | 52 Weeks |
Safety Issue: | |
Description: | Compared between DRL_RI with MabThera® in subjects with CD20 positive, LTB FL |
Measure: | Overall response rate |
Time Frame: | 12 Weeks |
Safety Issue: | |
Description: | Compared between DRL_RI with MabThera® in subjects with CD20 positive, LTB FL |
Measure: | Overall survival |
Time Frame: | 52 Weeks/End of Study |
Safety Issue: | |
Description: | Compared between DRL_RI with MabThera® in subjects with CD20 positive, LTB FL |
Measure: | Duration of response |
Time Frame: | 52 Weeks/End of Study |
Safety Issue: | |
Description: | Compared between DRL_RI with MabThera® in subjects with CD20 positive, LTB FL |
Measure: | Safety in terms of Adverse Events |
Time Frame: | 52 Weeks |
Safety Issue: | |
Description: | Compared between DRL_RI with MabThera® in subjects with CD20 positive, LTB FL in terms of Adverse events (AEs) as assessed by the NCI CTCAE version 5.0. |
Measure: | Tolerability in terms of Adverse Events |
Time Frame: | 52 Weeks |
Safety Issue: | |
Description: | Compared between DRL_RI with MabThera® for subjects with severity (Grade 3 or Higher) of Treatment Emergent Adverse Events, as assessed by the NCI CTCAE v5.0. |
Measure: | Analysis of BAb and NAb in Blood |
Time Frame: | 52 Weeks |
Safety Issue: | |
Description: | Immunogenicity compared between DRL_RI with MabThera® in subjects with CD20 positive, LTB FL in terms of Anti-DRL_RI antibodies |
Details
Phase: | Phase 3 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Dr. Reddy's Laboratories Limited |
Trial Keywords
- Follicular Lymphoma
- Dr. Reddy's Rituximab
- Biosimiliar (DRL_RI)
- FLINTER
Last Updated
April 9, 2020